• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian Journal of Neurological Sciences: le Journal Canadien des Sciences Neurologiques >Brivaracetam: First Canadian Experience in an Intractable Epilepsy Population
【24h】

Brivaracetam: First Canadian Experience in an Intractable Epilepsy Population

机译：Brivaracetam：顽固性癫痫患者的第一次加拿大经验

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To evaluate the effectiveness and tolerability of brivaracetam (BRV) in a refractory epilepsy population in an outpatient clinical setting. Methods: Retrospective medical information system review and self-report questionnaire for all patients treated with BRV until the end of 2017. Results: Thirty-eight patients were included, 73.7% female and mean age 36.2. The mean number of antiepileptic drugs (AEDs) for previous use was 8.9, and for current use was 2.5. Mean seizure frequency in the last 3 months was 12 per month. At 3, 6, 12, and 15 months, the 50% responder rates were 36.1%, 32%, 41.2%, and 45.5%, respectively. Patients took BRV for a median duration of 8.25 months, ranging from 7 days to 60 months. Retention rate was 75.0%, 72.0%, 59.2%, and 47.9% at 3, 6, 12, and 15 months, respectively. Overall, the main reasons for discontinuation were adverse events (AEs) (52.3%), lack of efficacy (35.3%), or both (11.8%). The rate of total AEs was 60.5% according to medical records and 85.7% according to questionnaire, including mostly tiredness, psychiatric, and memory complaints. Psychiatric side effects occurred in 31.6% according to medical records and 47.4% according to questionnaire results, which is higher than previously reported and persisted throughout the study period. Conclusions: BRV appears to be a useful and safe add-on treatment, even in a very refractory group of patients. In this real-life clinical setting, psychiatric AEs were found at a higher rate than previously published.
机译：目的：评价在门诊临床环境中难治性癫痫群中Brivaracetam（BRV）的有效性和耐受性。方法：回顾性医疗信息系统审查和自我报告问卷，所有患者对BRV治疗到2017年底。结果：包括三十八名患者，女性和平均年龄为36.2岁。以前使用的抗癫痫药物（AED）的平均数量为8.9，目前使用为2.5。过去3个月的平均癫痫发作频率每月12个月。在3,6,12和15个月，50％的响应率分别为36.1％，32％，41.2％和45.5％。患者患有3.25个月的中位数，从7天到60个月的中位。保留率分别为75.0％，72.0％，59.2％，分别为3,6,12和15个月的47.9％。总体而言，停止不良的主要原因是不良事件（AES）（52.3％），缺乏疗效（35.3％）或两者（11.8％）。根据医疗记录，总AE的率为60.5％，根据调查问卷，包括大多数疲劳，精神病和记忆投诉的85.7％。根据医疗记录的情况，精神病副作用在31.6％发生，根据调查表结果，47.4％，高于先前报告并在整个研究期间持续存在。结论：即使在一个非常难治性的患者中，BRV似乎是一种有用和安全的附加治疗。在这种真实临床环境中，精神病患者以比以前发表的更高的速度被发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号